GlobeNewswire

Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
10/11/2026
94% of participants maintained seroresponse five years after a single vaccination Comparable antibody persistence observed in older (65+) and younger adults Data further reinforce IXCHIQ ® 's differentiated profile with [...]
Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®
10/11/2026
94% des participants ont maintenu une séroréponse cinq ans après une dose unique du vaccin La persistance des anticorps chez les adultes âgés de 65 ans et plus est comparable à celle des jeunes adultes Ces données [...]
Australian therapy aimed at halting MND progression and restoring function advances to national Phase 2 trial
10/11/2026
Video interviews, overlay and photos here BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by [...]
Harrow Announces Third Quarter 2026 Financial Results
09/11/2026
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
09/11/2026
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA [...]
Xenon Reports Q3 2026 Financial Results and Provides Business Update
09/11/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies [...]
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
09/11/2026
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
09/11/2026
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track [...]
SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
09/11/2026
Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of Smallpox NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies (NASDAQ: SIGA), a commercial stage [...]
IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09/11/2026
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious [...]
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
09/11/2026
The Board approved plan target s a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q 1 202 7 Cost [...]
Five Vital Nutrients Bestsellers Earn TESTED by SuppCo Certification Verifying Label Claims
09/11/2026
MIDDLETOWN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vital Nutrients , a practitioner-founded nutritional supplement company, today announced that five of its dietary supplements have earned TESTED by SuppCo [...]
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09/11/2026
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the hiring, [...]
Robert Whitfield MD PLLC Marks Two Years of the SHARP Method, Drawing Surgical Patients From 40 States and Abroad
09/11/2026
First published by board-certified plastic surgeon Dr. Robert Whitfield in his book two years ago, the program pairs individualized health assessment before surgery with patient education and in-clinic recovery support [...]
Digbi Health Reports 18.4% Weight Loss With Tirzepatide, Challenges One-Size-Fits-All GLP-1 Care
09/11/2026
Real-world results from 3,181 members across 10 employers, to be presented at Obesity Week® 2026, beat every published cohort on the same drug with standard care. The difference: precision biology and AI that [...]
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
09/11/2026
LAKEWOOD, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality control solutions and life sciences [...]
Cellectis to Report Third Quarter Financial Results on November 12, 2026
09/11/2026
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of [...]
Cellectis publiera ses résultats financiers du troisième trimestre le 12 novembre 2026
09/11/2026
NEW YORK, 09 nov. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société d’ingénierie du génome qui développe des médicaments génétiques destinés à des maladies aujourd’hui traitées à vie, [...]
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
09/11/2026
SUNNYVALE, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum